NCT07051486View on ClinicalTrials.gov

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

August 31, 2026

Conditions
Recurrent or Metastatic Cervical Cancer
Interventions
DRUG

SHR-A1811 Injection

SHR-A1811 for injection.

Trial Locations (2)

250063

Shandong University Qilu Hospital, Jinan

350011

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY